enabling technologies and future implant solutions. Furthermore, the company’s scale and operational discipline will help optimize Nevro’s financial performance, driving enhanced profitability ...

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased 14.2% year over year. During the fourth quarter of 2024, Nevro made significant ...

U.S. revenue saw a decline of 9.9% to $91.4 million, with decreases in both permanent implant and trial procedures. International revenue also fell by 3.8% to $14.1 million. Nevro’s adjusted ...

According to GMED administration, the deal allows them to expand into new markets for future growth while gaining access to Nevro’s world-class, differentiated technologies that can provide ...

StockNews.com started coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report released on Monday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.